Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Comparison of Jinzhen oral liquid and ambroxol hydrochloride and clenbuterol hydrochloride oral solution in the treatment of acute bronchitis in children: A multicenter, non-inferiority, prospective, randomized controlled trial.
Acta Pharm Sin B
December 2024
Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
The comparison between traditional Chinese medicine Jinzhen oral liquid (JZOL) and Western medicine in treating children with acute bronchitis (AB) showed encouraging outcomes. This trial evaluated the efficacy and safety of the JZOL for improving cough and expectoration in children with AB. 480 children were randomly assigned to take JZOL or ambroxol hydrochloride and clenbuterol hydrochloride oral solution for 7 days.
View Article and Find Full Text PDFDevelopment and Characterization of Spray-Dried Combined Levofloxacin-Ambroxol Dry Powder Inhaler Formulation.
Pharmaceutics
November 2024
Pharmacy Discipline, School of Clinical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4000, Australia.
This study explores the development and characterization of spray-dried composite microparticles consisting of levofloxacin (LVX, a broad-spectrum antibiotic), and ambroxol (AMB, a mucolytic agent that has antibacterial and antibiofilm properties), for the intended application of the drug against lower respiratory tract infections (LRTIs). A range of LVX to AMB mass ratios (1:1, 1:0.5, and 1:0.
View Article and Find Full Text PDFBroaden properties of ambroxol hydrochloride as an antibiofilm compound.
Rev Argent Microbiol
December 2024
Lab. De Biofilms Microbianos, Dept. de Microbiología, Inst. de Investigaciones Biológicas Clemente Estable, Av. Italia 3318, Montevideo, Uruguay. Electronic address:
Biofilm-associated microorganisms can cause many infections and are an important cause of resistance to several antimicrobials. The antibiotic crisis has led to a pressing need for new therapeutic tools. Ambroxol is frequently used as a mucolytic agent in respiratory diseases with increased mucus production.
View Article and Find Full Text PDFEfficacy of Ambroxol Combined with Loquat Syrup on Bacterial Pneumonia in Mice.
J Inflamm Res
November 2024
Department of Pulmonary and Critical Care Medicine (PCCM), The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People's Republic of China.
Article Synopsis
- The study examines the effectiveness of combining ambroxol and loquat syrup to treat bacterial pneumonia, a serious respiratory disease.
- Mice with pneumonia induced by P. aeruginosa were tested to see how well this combination worked compared to using either drug alone.
- Results showed that the combined treatment improved the expulsion of bacteria from saliva and significantly reduced lung damage and inflammation, indicating a potential new treatment approach for bacterial pneumonia.
Unveiling the antibacterial action of ambroxol against Staphylococcus aureus bacteria: in vitro, in vivo, and in silico investigation.
BMC Microbiol
November 2024
Pharmaceutical Microbiology Department, Faculty of Pharmacy, Tanta University, Tanta, 31527, Egypt.
Article Synopsis
- The increasing issue of multidrug resistance (MDR) in pathogenic bacteria like Staphylococcus aureus has prompted the search for new treatment methods, including FDA-drug repurposing.
- Ambroxol was tested against clinical MDR S. aureus isolates and showed effective antibacterial activity, with concentrations needed to inhibit growth between 0.75 to 1.5 mg/mL, and also disrupted biofilm formation in about 42% of the isolates.
- In vivo studies demonstrated ambroxol's ability to enhance skin tissue healing in S. aureus infected burn injuries by reducing bacterial presence and inflammation, with further investigations suggesting its action may involve binding to several targets in the bacterium.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!